Avivagen (OTCMKTS:VIVXF – Get Free Report) and Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.
Earnings & Valuation
This table compares Avivagen and Capricor Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avivagen | N/A | N/A | N/A | ($0.04) | N/A |
| Capricor Therapeutics | $22.27 million | 77.91 | -$105.04 million | ($2.32) | -12.91 |
Analyst Ratings
This is a summary of recent ratings for Avivagen and Capricor Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avivagen | 0 | 0 | 0 | 0 | 0.00 |
| Capricor Therapeutics | 1 | 0 | 9 | 0 | 2.80 |
Capricor Therapeutics has a consensus price target of $48.36, indicating a potential upside of 61.43%. Given Capricor Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Avivagen.
Insider and Institutional Ownership
21.7% of Capricor Therapeutics shares are owned by institutional investors. 2.1% of Avivagen shares are owned by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Avivagen and Capricor Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avivagen | N/A | N/A | N/A |
| Capricor Therapeutics | N/A | -59.27% | -48.65% |
Summary
Capricor Therapeutics beats Avivagen on 6 of the 9 factors compared between the two stocks.
About Avivagen
Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Receive News & Ratings for Avivagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avivagen and related companies with MarketBeat.com's FREE daily email newsletter.
